共 50 条
Systemic Therapy of Atopic Dermatitis: Welcome to the Revolution
被引:0
|作者:
Eichenfield, Lawrence F.
[1
,2
,3
,4
]
Gold, Linda F. Stein
[5
]
机构:
[1] Univ Calif San Diego, Sch Med, Dermatol & Pediat, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Sch Med, Dept Dermatol, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, Pediat & Adolescent Dermatol, La Jolla, CA 92093 USA
[4] Univ Calif, Rady Childrens Hosp, San Diego, CA USA
[5] Henry Ford Hlth Syst, Dermatol Res, Detroit, MI USA
关键词:
Atopic dermatitis;
dupilumab;
fezakinumab;
JAK inhibitors;
lebrikizumab;
nemolizumab;
systemic therapy;
tralokinumab;
PLACEBO;
MANAGEMENT;
DUPILUMAB;
TRIAL;
D O I:
10.12788/j.sder.2017.051
中图分类号:
R75 [皮肤病学与性病学];
学科分类号:
100206 ;
摘要:
Until recently, systemic therapy of atopic dermatitis was limited to off-label use of immunomodulators, which can pose significant safety concerns, and treatment with systemic corticosteroids, not recommended in the most recent guidelines. The introduction of dupilumab in 2017 marked a major advance in systemic therapy for atopic dermatitis. It has demonstrated long-term efficacy in adults with moderate to severe disease, and is being studied in children. Several other biologic agents and "small molecules" with varying mechanisms of action are in phase 2 or 3 development. (C) 2017 published by Frontline Medical Communications
引用
收藏
页码:S103 / S105
页数:3
相关论文